The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInsig Ai Plc Regulatory News (INSG)

Share Price Information for Insig Ai Plc (INSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 16.50
High: 16.50
Low: 16.50
Prev. Close: 16.50
INSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Equity subscription

24 Apr 2023 07:02

RNS Number : 1422X
Insig AI Plc
24 April 2023
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of  UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

24 April 2023

Insig AI plc

("Insig AI" or the "Company")

 

Equity subscription raising £0.9 million and

PDMR Dealing

 

The Company is pleased to announce that it has successfully raised £0.9 million by way of equity subscription for 5,294,118 ordinary shares of 1 pence each in the Company ("Subscription Shares") at 17 pence per Ordinary Share (the "Subscription Price")(the "Subscription").

The Subscription Price was the closing price of the Ordinary Shares on 20 April 2023.

£0.45 million of the Subscription is from a new institutional investor. Richard Bernstein, Insig AI Chairman, also subscribed for approximately £0.15 million. Further details of Richard Bernstein's subscription are provided in the PDMR dealing table at the end of this announcement.

It is intended that the proceeds of the Subscription will be utilised to invest in sales and marketing as well as for working capital purposes. Given the board's expectations for revenues and profitability, it is expected that save for potential strategic partnership or corporate opportunities, the Group will not need to raise any further equity for working capital purposes in the short to medium term.

The Subscription Shares will be issued from Treasury, from shares gifted to the Company in December 2022 by founders Steve Cracknell and Warren Pearson, Chief Product Officer and Chief Technology Officer. Specifically, 1,764,705 Subscription Shares will be issued on 27 April 2023 with the balance of 3,529,413 Subscription Shares being issued on 23 June 2023.

Fair and reasonable assessment

The subscription by Richard Bernstein, a director of the Company constitutes a related party transaction under the AIM Rules.

The directors of the Company (excluding Richard Bernstein), having consulted with Zeus Capital Limited, the Company's nominated adviser, consider that the terms of the Subscription and Richard's participation therein, are fair and reasonable insofar as the Company's shareholders are concerned.

Total voting rights

Following the issue of 1,764,705 Subscription Shares on 27 April 2023 out of treasury, the issued share capital of the Company will remain unchanged at 105,675,645 ordinary shares, whilst the total number of voting rights in the Company will be 103,969,763. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Following the transaction, the Company will hold 5,235,295 shares in treasury.

The Company will release a further announcement on the total voting rights of the Company following the issue of the balance of 3,529,413 Subscription Shares on 23 June 2023.

 

For further information, please visit www.insg.ai or contact: 

 

Insig AI plc

Richard Bernstein (chairman)

Colm McVeigh (CEO)

 richard.bernstein@insg.ai

colin.mcveigh@insg.ai

Zeus (Nominated Adviser & Broker)

David Foreman / James Hornigold / Danny Philips

+44 (0)20 3829 5000

 

 

The information set out below is provided in accordance with the requirements of Article 19 of the Market Abuse Regulation.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")

 

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Richard Bernstein

2

Reason for notification

a.

Position/Status

Non-Executive Chairman

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Insig AI plc

b.

LEI

21380098CKBAG1NWCD98

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary Shares of 1p each

GB00BYV31355

b.

Nature of the transaction

Purchase of shares 

c.

Price(s) and volume(s)

Transaction 1 (settlement 27 April 2023)

Transaction 2 (settlement June 2023)

 

Price(s)

Volume(s)

17.0p

291,503

 

17.0p

 

583,006

d.

Aggregated information

 

Price(s)

Volume(s)

17.0p

874,509

e.

Date of the transaction

21/04/2023

f.

Place of the transaction

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUORURONUSUUR
12
Date   Source Headline
17th Apr 20247:00 amRNSDirector/PDMR Shareholding
4th Apr 20247:00 amRNSFunding facility, share allotment & PDMR dealing
2nd Apr 20247:00 amRNSTrading update & equity funding facility proposal
28th Dec 20237:00 amRNSInclusion within UN Environment Programme Tool
22nd Dec 20237:00 amRNSDirector/PDMR Shareholding
21st Dec 20237:00 amRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSInterim results
28th Nov 20237:00 amRNSAppointment of investor relations adviser and TVR
27th Nov 20237:00 amRNSCorporate development adviser and TVR
15th Nov 20237:00 amRNSDisposal, Loan Conversion, New Project Win & TVR
30th Oct 20237:00 amRNSNew Product Launch
28th Sep 20237:00 amRNSAppointment of Strategic Adviser and TVR
15th Sep 20233:56 pmRNSResult of AGM
15th Sep 20237:00 amRNSAGM Statement
30th Aug 20237:00 amRNSDirector/PDMR Shareholding
24th Aug 20237:00 amRNSDirector/PDMR Shareholding
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSFinal Results, Posting of Report and Notice of AGM
1st Aug 20234:42 pmRNSChange of Registered Office
31st Jul 20235:30 pmRNSTotal Voting Rights
4th Jul 20237:00 amRNSRevision of Convertible Loan Facility Agreement
19th May 20237:00 amRNSDirector/PDMR Shareholding
11th May 20237:00 amRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Apr 20237:00 amRNSDeath of Director
24th Apr 20237:02 amRNSEquity subscription
24th Apr 20237:01 amRNSInsig AI Data & Technology Collaboration with FCA
24th Apr 20237:00 amRNSTrading and operations update
9th Mar 20237:00 amRNSInsig AI showcase Generative AI Product Capability
6th Feb 20237:00 amRNSGenerative AI Product Capability
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
9th Jan 20237:00 amRNSConvertible Loan Facility Drawdown
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20227:00 amRNSDirector Dealing
22nd Dec 20227:00 amRNSRevision of Convertible Loan Facility Agreements
21st Dec 20227:00 amRNSDirectors gift shares to Company treasury & TVR
19th Dec 20227:00 amRNSInterim Results
8th Nov 20227:00 amRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSNew Contract Win
3rd Nov 20227:00 amRNSTrading update
26th Oct 20227:00 amRNSConvertible Loan Facility drawdown
17th Oct 20227:00 amRNSPartnership agreement with BRAIN
12th Oct 20227:00 amRNSConvertible Loan Facility Agreement and drawdown
30th Sep 202212:13 pmRNSResult of Annual General Meeting & General Meeting
30th Sep 20227:00 amRNSContract win
26th Sep 20227:00 amRNSConvertible Loan Facility drawdown
20th Sep 20227:00 amRNSChange of Registered Office
12th Sep 20227:00 amRNSConvertible Loan Facility Agreement
9th Sep 20227:00 amRNSFinal Results, Posting of Report and Notice of GM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.